Last reviewed · How we verify
NCT06833060: TSLT project
Transscleral Selective Laser Trabeculoplasty Project
NA trial testing Selective Laser Trabeculoplasty in Glaucoma,Open-Angle in 15 participants. Currently enrolling.
1 November 2025
Quick facts
| Lead sponsor | Lumibird Medical (Quantel Medical, Ellex Medical, Optotek) |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | device feasibility |
| Enrollment | 15 |
| Start date | 19 June 2025 |
| Primary completion | 1 November 2025 |
| Estimated completion | 1 November 2025 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Selective Laser Trabeculoplasty
Conditions studied
- Glaucoma,Open-Angle — all drugs for Glaucoma,Open-Angle →
- Ocular Hypertension (OH) — all drugs for Ocular Hypertension (OH) →
Sponsor
Lumibird Medical (Quantel Medical, Ellex Medical, Optotek)
Who can join
18 and older, any sex, with Glaucoma,Open-Angle or Ocular Hypertension (OH). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this clinical trial is to determine how safe and effective (how well it works) the ELLEX TSLT device is for the treatment of Glaucoma and Ocular Hypertension using Transscleral Selective Laser Trabeculoplasty. Selective Laser Trabeculoplasty (SLT) is a type of laser therapy that uses short pulses of low-energy light to lower eye pressure. This treatment uses a lens in contact with the front part of the eye (called cornea) which may lead to complications. Transscleral Selective Laser Trabeculoplasty allows the doctor to perform the laser treatment without the lens coming into contact with the cornea, potentially offering a simpler, quicker and safer approach for both participants and doctors. Participants will be required to attend four study visits. The first visit will assess the disease, the second will involve the TSLT laser treatment for the participant's condition (glaucoma or ocular hypertension), and the final two visits, at 1 day and 30 days post-treatment, will evaluate the treatment's efficacy and the procedure's safety.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06833060
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Selective Laser Trabeculoplasty
Trials testing the same drug.
- NCT04036214 — Efficacy and Safety Outcomes of Optometrist Performed Selective Laser Trabeculoplasty (SLT) · unknown
- NCT03164941 — Effect of SLT Location on Treatment Outcomes · unknown
- NCT02636946 — A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hyperte · Phase 3 · completed
- NCT02507687 — Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glau · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06833060 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lumibird Medical (Quantel Medical, Ellex Medical, Optotek)
- Last refreshed: 26 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06833060.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing